Neurogene has a $903M market cap with two phase 1/2 assets, NGN-401 for Rett Syndrome and NGN-101 for CLN5 Batten Disease.
How techniques like model pruning, quantization and knowledge distillation can optimize LLMs for faster, cheaper predictions.
Partly in light of three new Arm Cortex CPUs launching at Computex in June, Chris Bergey, Arm Senior Vice President and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback